FDA EIR - CMC Biologics - June 06, 2014

An FDA Pre-Approval Inspection of CMC Biologics was conducted from June 1 to June 6, 2014. The inspection's primary objective was to evaluate the company's quality system for compliance with current Good Manufacturing Practices (cGMP). The report highlighted CMC Biologics' robust Quality Unit, consisting of independent Quality Assurance (QA) and Quality Control (QC) departments, both reporting directly to the Chief Operating Officer. QA's extensive responsibilities include ensuring cGMP compliance, managing quality-related complaints, and the meticulous review and approval of critical documentation such as master and batch production records, validation protocols, and change controls. Furthermore, QA is responsible for the final disposition of all Master Cell Banks, Working Cell Banks, raw materials, and Active Pharmaceutical Ingredients (APIs). The company's quality system effectiveness is regularly monitored through quarterly Quality Reports to Management, tracking key performance indicators like deviations, corrective actions, and audits. Notably, the inspection concluded with "No objectionable conditions noted" concerning the quality system, indicating strong adherence to regulatory standards. Consequently, no specific violations or immediate corrective actions were identified within this segment of the inspection report.